References
- IMPT. MPT product development database; [cited 2017 Oct 11]. Available from: http://mpts101.org/mpt-database
- Bustreo F. Ten top issues for women’s health; [cited 2017 Dec 20]. Available from: www.who.int/life-course/news/commentaries/2015-intl-womens-day/en
- Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014;45:301–314.
- WHO. Global Health Observatory (GHO) data: mortality and global health estimates; [cited 2017 Oct 11]. Available from: www.who.int/gho/mortality_burden_disease/en
- Gottlieb SL, Deal CD, Giersing B, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine. 2016;34:2939–2947.
- WHO. Sexual and reproductive health beyond 2014: equality, quality of care and accountability; [cited 2017 Oct 11]. Available from: http://apps.who.int/iris/bitstream/10665/112291/1/WHO_RHR_14.05_eng.pdf
- Sarkar DNN. Barriers to condom use. Eur J Contracept Reprod Health Care. 2008;13:114–122.
- IMPT. CCTN and MPT stakeholder round table on hormonal contraception (HC) in MPTs; [2015; cited 2017 Oct 11]. Available from: www.theimpt.org/resource-results/33-presentations/516-women-s-health-in-women-s-hands-the-promise-of-mpts-2
- IMPT. Technical meeting on hormonal contraception (HC) in MPTs; [2016; cite 2017 Oct 11]. Available from: www.theimpt.org/resource-results/51-technical-brief/654-technical-meeting-on-hormonal-contraception-hc-in-mpts
- CONRAD. CONRAD launches first-ever multipurpose vaginal ring clinical trial; [cited 2017 Oct 11]. Available from: www.conrad.org/news-pressreleases-105.html
- IPM. IPM advances three-month HIV prevention and contraception ring to clinical trial; [cited 2017 Oct 11]. Available from: www.ipmglobal.org/content/ipm-advances-three-month-hiv-prevention-and-contraception-ring-clinical-trial
- IMPT. Meeting summary: technical meeting on hormonal contraceptives in MPTs. Washington, DC; 2014 Sept 18–19; [cited 2017 Oct 11]. Available from: www.theimpt.org/documents/IMPT-HC-Summary-Report2014.pdf
- Mansoor LE, Karim QA, Yende-Zuma N, et al. Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav. 2014;18:811–819.
- Gengiah TN, Moosa A, Naidoo A, et al. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014;36:70–85.
- Dellar RC, Dlamini S, Karim QA. Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc. 2015;18:19408.
- Schelar E, Polis CB, Essam T, et al. Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products. Contraception. 2016;93:32–43.
- Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
- Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS One. 2016;11:e0147743.
- Nel AM, Coplan P, van de Wijgert JH, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS. 2009;23:1531.
- Romano J, Brady M, Manning J. Nonclinical development needs and regulatory requirements for multipurpose prevention technologies: a primer; [cited 2017 Dec 21]. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.303.3932&rep=rep1&type=pdf
- Sedgh G, Hussain R. Reasons for contraceptive nonuse among women having unmet need for contraception in developing countries. Stud Fam Plann. 2014;45:151–169.
- Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod. 1996;11:20–23.
- Bitzer J, Simon JA. Current issues and available options in combined hormonal contraception. Contraception. 2011;84:342–356.
- Stegeman BH, Bastos M, de, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298.
- Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66:240–250.
- Federal Register. Drug interactions with hormonal contraceptives: public health and drug development implications; public meeting; [cited 2017 Oct 11]. Available from: www.federalregister.gov/documents/2015/09/11/2015-22949/drug-interactions-with-hormonal-contraceptives-public-health-and-drug-development-implications
- Berry-Bibee EN, Kim M-J, Tepper NK, et al. Co-administration of St. John's wort and hormonal contraceptives: a systematic review. Contraception. 2016;94:668–677.
- Berry-Bibee EN, Kim M-J, Simmons KB, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94:650–667.
- Reimers A, Brodtkorb E, Sabers A. Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations. Seizure. 2015;28:66–70.
- Nanda K, Stuart GS, Robinson J, et al. Drug interactions between hormonal contraceptives and antiretrovirals. AIDS Lond Engl. 2017;31:917–952.
- Scarsi KK, Darin KM, Chappell CA, et al. Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV. Drug Saf. 2016;39:1053–1072.
- Cherala G, Edelman A, Dorflinger L, et al. The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy. Contraception. 2016;94:104–108.
- Endrikat J, Gerlinger C, Richard S, et al. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 2011;84:549–557.
- Han L, Taub R, Jensen JT. Cervical mucus and contraception: what we know and what we don't. Contraception. 2017;96:310–321.
- Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;8:CD008452.
- ECHO. ECHO study; [cited 2017 Oct 11]. Available from: http://echo-consortium.com/echo-study-3
- Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS Lond Engl. 2016;30:2665–2683.
- Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19–26.
- Hapgood JP, Kaushic C, Hel Z. Hormonal contraception and HIV-1 acquisition: biological mechanisms. Endocr Rev. 2018;39:36–78.
- Byrne EH, Anahtar MN, Cohen KE, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis. 2016;16:441–448.
- Chandra N, Thurman AR, Anderson S, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses. 2013;29:592–601.
- Polis CB, Phillips SJ, Hillier SL, et al. Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals? Aids Lond Engl. 2016;30:2571–2576.
- WHO. Hormonal contraceptive eligibility for women at high risk of HIV. Guidance statement; [cited 2017 Oct 11]. Available from: www.who.int/reproductivehealth/publications/family_planning/HC-and-HIV-2017/en
- Rodriguez-Garcia M, Patel MV, Shen Z, et al. Tenofovir inhibits wound healing of epithelial cells and fibroblasts from the upper and lower human female reproductive tract. Sci Rep. 2017;7:45725.
- Klot JF, Wira CR. Sexual violence and genital injury: the physiology of HIV transmission risk. Am J Reprod Immunol. 2013;69:2–3.
- Winston A, Post FA, DeJesus E, et al. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Lancet HIV. 2018;5:e162–e171.
- Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331–e340.
- Sugarman J. Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials. Curr Opin HIV AIDS. 2016;11:109–115.
- Cutrell A, Donnell D, Dunn DT, et al. HIV prevention trial design in an era of effective pre-exposure prophylaxis. HIV Clin Trials. 2017;18:177–188.
- Brady M, Park H. What regulatory guidance exists for multipurpose prevention technologies (MPTs)? A review of key guidance documents and their applicability to MPTs. [2011; cited 2017 Oct 11]. Available from: http://resource.cami-health.org/documents/What%20Regulatory%20Guidance%20Exists%20for%20MPTs.%20Pop%20Council.pdf
- Dellplain L, Young Holt B, Hemmerling A, et al. Market access framework for multipurpose prevention technology (MPT) development and introduction; [2016; cited 2017 Oct 11]. Available from: www.theimpt.org/documents/presentations/MarketAccessFrameworkMPT-012116.pdf
- Dellplain L, Thomas V, Russell E, et al. Laying the groundwork for a strategic evaluation framework (SEF) for HIV prevention and MPT product development; [cited 2017 Oct 11]. Available from: www.theimpt.org/documents/breif/IMPT_Activity1Report_Final122116.pdf
- IMPT. Strategic evaluation framework (SEF) for MPTs: strategic target profile context summaries; [cited 2017 Oct 11]. Available from: www.theimpt.org/documents/reports/SEF-NextSteps-Report_FY17.pdf
- DiLiberti C, Dorflinger L, Romano J. Bioavailability/bioequivalence strategies for MPTs – feasibility and risks; [cited 2018 Jan 28]. Available from: www.theimpt.org/multi-media/Bioavailability_Bioequivalence%20Webinar%20Audio_26%20Jan%202017.mp4
- USAID. Idea to impact: a guide to introduction and scale; [2015; cited 2017 Oct 11]. Available from: www.usaid.gov/cii/guide-introduction-and-scale
- Brady M, Manning J. Lessons from reproductive health to inform multipurpose prevention technologies: don’t reinvent the wheel. Antiviral Res. 2013;100:S25–S31.
- IMPT. IMPT annual report; [2016; cited 2018 Feb 21]. Available from: www.theimpt.org/resource-results/70-reports-annual/1053-2016-impt-annual-report2
- NIH. Next generation multipurpose prevention technologies (NGM); [cited 2017 Nov 11]. Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-17-028.html#CT
- NIH. Advancing the science of multipurpose technology for the prevention of HIV and unintended pregnancy (R43/R44); [cited 2017 Nov 11]. Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-18-102.html
- NIH. Contraception research centers program (U54); [cited 2017 Nov 11]. Available from: https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-18-035.html
- CEPI. Mission; [cited 2018 Jul 9]. Available from: http://cepi.net/mission
- Boonstra H, Young Holt B. Multipurpose prevention technologies hold great promise, but more US investment is needed; [2015; cited 2017 Dec 20]. Available from: http://thehill.com/blogs/congress-blog/healthcare/261512-multipurpose-prevention-technologies-hold-great-promise-but